Search results
Results from the WOW.Com Content Network
Dicloxacillin is a narrow-spectrum β-lactam antibiotic of the penicillin class. [1] It is used to treat infections caused by susceptible (non-resistant) Gram-positive bacteria . [ 1 ] It is active against beta-lactamase -producing organisms such as Staphylococcus aureus , which would otherwise be resistant to most penicillins .
Cloxacillin is used against staphylococci that produce beta-lactamase, due to its large R chain, which does not allow the beta-lactamases to bind. This drug has a weaker antibacterial activity than benzylpenicillin, and is devoid of serious toxicity except for allergic reactions. [citation needed]
to share – to copy, distribute and transmit the work; to remix – to adapt the work; Under the following conditions: attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
The two types of beta-lactamases work on the basis of the two basic mechanisms of opening the β-lactam ring. [2] The SBLs are similar in structure and mechanistically to the β-lactam target penicillin-binding proteins (PBPs) which are necessary for cell wall building and modifying. SBLs and PBPs both covalently change an active site serine ...
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
The usual dose by mouth is one capsule of 250 mg 4 times a day in adults and half the adult dose as a syrup for children under the age of 10 years but over 2. [4] For children below the age of 2 years, the oral dose is a quarter of the adult oral dose. [3] Ampicillin/flucloxacillin is taken orally about half an hour before food. [5]
Backbone structure of a carbapenem. Carbapenems are a class of very effective antibiotic agents most commonly used for treatment of severe bacterial infections.This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections.
The FDA approved dalbavancin for use to treat MRSA infections in adults on May 23, 2014. Dalbavancin is intended to treat acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bacteria like Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains) and Streptococcus pyogenes .